Titre:
  • Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Auteur:Stewart, A Keith; Rajkumar, Vincent SV; Dimopoulos, Meletios Athanassios; Masszi, Tamás; Špička, Ivan; Oriol, Albert; Hájek, Roman; Rosiñol, Laura; Siegel, David D.A.; Mihaylov, Georgi GG; Goranova-Marinova, Vesselina; Rajnics, Péter; Suvorov, Aleksandr; Niesvizky, Ruben; Jakubowiak, Andrzej AJ; San-Miguel, Jesus; Ludwig, Heinz; Wang, Michael; Maisnar, Vladimír; Minarik, Jiri; Bensinger, William WI; Mateos, Maria-Victoria; Ben Yehuda, Dina; Kukreti, Vishal; Zojwalla, Naseem; Tonda, Margaret E; Yang, Xinqun; Xing, Biao; Moreau, Philippe; Palumbo, Antonio; Meuleman, Nathalie; et al.
Informations sur la publication:The New England journal of medicine, 372, 2, page (142-152)
Statut de publication:Publié, 2015-01
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
Dexamethasone -- administration & dosage -- adverse effects
Female
Humans
Intention to Treat Analysis
Kaplan-Meier Estimate
Male
Middle Aged
Multiple Myeloma -- drug therapy -- mortality
Oligopeptides -- administration & dosage -- adverse effects
Recurrence
Thalidomide -- administration & dosage -- adverse effects -- analogs & derivatives
Langue:Anglais
Identificateurs:urn:issn:0028-4793
info:doi/10.1056/NEJMoa1411321
info:pmid/25482145